- This event has passed.
BioPharma Masterclass 2: The Art of Capital Raising – Negotiating the Investment Landscape
May 25, 2022 @ 8:30 am - 5:00 pm AEST
Event Navigation
This Masterclass Series is sponsored by the State Government of Victoria, Department of Jobs, Precincts and Regions.
Advancing Global Business Strategy for BioPharma is a customised program designed to support early-stage biopharma executives. Participants will gain valuable skills and methodologies to develop effective business and investment strategies, optimise investor interest and accelerate their path to market. Two Masterclasses will be delivered in July and September. To gain maximum value from the program, interested participants can register for the series at a discounted rate or register for one Masterclass of interest.
Masterclass 2: The Art of Capital Raising is part of our BioPharma Masterclass Series, which is kindly sponsored by the State Government of Victoria, Department of Jobs, Precincts and Regions.
Click here to explore the Masterclass Program Agenda
Masterclass 2: The Art of Capital Raising – Negotiating the Investment Landscape
This Masterclass Program has three components (delivered in-person):
- BioForum: 24 May 2022 | 4:00pm – 6:30pm | Gadens, Level 13, Collins Arch, 447 Collins Street, Melbourne
- Masterclass Workshop: 25 May 2022 | 8:30am – 5:00pm | Sofitel Melbourne on Collins, West Tower Suite, 25 Collins Street, Melbourne
- 30-minute advisory session: Individual meetings held on 26 or 27 May 2022
Registration for this Masterclass program includes:
- Three complimentary registrations for colleagues to attend the BioForum
- Attendance at the full-day Masterclass for one company representative
- One 30-minute advisory session (two company representatives from your organisation may attend)
About this Masterclass
- Take a deep dive into the art of capital raising
- Explore the global funding environment and learn critical factors for success when fundraising
- Learn the nuances of Corporate Venture Capital vs. Venture Capital and the impact on early-stage biopharma
- What’s in a VC pitch? Explore the art of the pitch, the VC diligence process and strategies to seal the deal
- Become familiar with key legal considerations when raising capital and negotiating investment documents
- Understand the nuances of capital: equity vs debt vs convertible note
- Gain practical insights for getting the “house in order” to attract and facilitate investment
- Learn key considerations and practical methodologies for negotiating terms sheets, shareholders’ agreements and subscription agreements
- Become familiar with key considerations for engaging staff: employees vs independent contractors
- Explore statutory frameworks for National Employment Standards and Modern Awards
- Learn the importance of employment contracts and tips for protecting your business
- Gain practical insights on the importance of protecting intellectual property
- Become familiar with key regulatory and market access issues
- Gain practical skills and insights for effective tax structuring
Leading Industry Experts
Gadens is a leading provider of legal services and recognised as a leading firm for advisory, transaction and disputes. They advise early stage companies through to large multinational pharmaceutical and medical device companies, as well as universities and research institutes. Read presenter bios below.
Support from Shawn Fu, Vice President, Vertex Ventures HC (USA).
Registration
Register for Masterclass:
- Members: $595
- Non-members: $695 p/p/masterclass
This is a high value Masterclass Series. Heavily subsidised rates are made possible with sponsorship from the State Government of Victoria. The estimated value p/p/masterclass is $3,500. Places are strictly limited and subject to confirmation by BioMelbourne Network. Unsure if your organisation is a member? Check our member directory
Cancellation policy: A full refund can be issued up to 14 days prior to the event only. No refunds can be issued within 14 days of the event. In the event of postponement due to Government restrictions, registrations will be carried forward to a new date. Should the program be cancelled, or you are unable to attend on the rescheduled date, a full refund will be made available.
Masterclass 2 speaker biographies:
Shawn Fu (USA) Vice President Vertex Ventures HC
Shawn is a Vice President at Vertex Ventures HC where he executes investments in the biotech and medical devices sectors.
Prior to Vertex, Shawn was a Vice President in JP Morgan’s Equity Research department in New York covering large cap biotechnology. Shawn was also previously an associate at Deallus Consulting, a London Based life sciences consulting firm where he performed global strategic projects for clients comprised of top 20 global biopharma companies.
Shawn holds an MD from UT Southwestern Medical School and a BS in Biology/Economics from Duke University.
Prior to Vertex, Shawn was a Vice President in JP Morgan’s Equity Research department in New York covering large cap biotechnology. Shawn was also previously an associate at Deallus Consulting, a London Based life sciences consulting firm where he performed global strategic projects for clients comprised of top 20 global biopharma companies.
Shawn holds an MD from UT Southwestern Medical School and a BS in Biology/Economics from Duke University.
Vaughan Petherbridge, Partner, Corporate, Gadens
Vaughan is a Partner in the Corporate and Commercial Team at Gadens. He has over 20 years of experience at top-tier law firms and in-house in Australia and the United States.
Specialising in corporate and commercial law, Vaughan’s work focuses on mergers and acquisitions (M&A), early stage investing, joint ventures, complex business separations and transitional arrangements, and general corporate advisory work.
Vaughan has successfully led and closed a number of multi-million dollar domestic and cross-border transactions across a range of industries while managing teams of lawyers and other stakeholders. He has extensive experience in financial services, fintech and other emerging technologies and takes a practical and commercial approach to the provision of legal advice.
Specialising in corporate and commercial law, Vaughan’s work focuses on mergers and acquisitions (M&A), early stage investing, joint ventures, complex business separations and transitional arrangements, and general corporate advisory work.
Vaughan has successfully led and closed a number of multi-million dollar domestic and cross-border transactions across a range of industries while managing teams of lawyers and other stakeholders. He has extensive experience in financial services, fintech and other emerging technologies and takes a practical and commercial approach to the provision of legal advice.
Winnie Sinn, Partner, Gadens
Winnie is a Partner at Gadens. She has over 10 years of experience acting for a broad range of clients both in Australia as well as Hong Kong, where she is also admitted.
Winnie's practice is focused on corporate and commercial work, and includes advising clients from start-ups to large multinational companies on corporate governance, capital raisings, exit events (such as mergers and acquisitions or IPOs) and general commercial contract advice. She has a breadth of experience in various industries, including medtech, information technology, manufacturing and transport and logistics, and is known for her approachability and pragmatic approach to legal advice.
Winnie's practice is focused on corporate and commercial work, and includes advising clients from start-ups to large multinational companies on corporate governance, capital raisings, exit events (such as mergers and acquisitions or IPOs) and general commercial contract advice. She has a breadth of experience in various industries, including medtech, information technology, manufacturing and transport and logistics, and is known for her approachability and pragmatic approach to legal advice.
Louise Rumble, Partner, Employment Advisory Group, Gadens
Louise is a Partner in the Employment Advisory Group at Gadens with over 15 years' experience providing strategic and commercial advice to clients, equipping them with the knowledge to provide the best outcomes for their employees and business.
Louise brings a considered, holistic approach to navigating employment matters in order to achieve pragmatic and commercial solutions. Her experience has involved advising clients across a range of sectors including health, energy, infrastructure, media, arts, security, logistics and professional services.
Louise regularly presents on workplace issues covering the Fair Work Ombudsman’s powers and enforcement activities and gender equality in the workplace.
Louise brings a considered, holistic approach to navigating employment matters in order to achieve pragmatic and commercial solutions. Her experience has involved advising clients across a range of sectors including health, energy, infrastructure, media, arts, security, logistics and professional services.
Louise regularly presents on workplace issues covering the Fair Work Ombudsman’s powers and enforcement activities and gender equality in the workplace.
Kelly Griffiths, Partner, Disputes and Investigations, Gadens
Kelly is as Partner in the Commercial Disputes Team at Gadens, specialising in regulatory investigations and litigation, including biotechnology and pharmaceutical, corporate crime and intellectual property law.
Prior to joining Gadens, Kelly served as both Chief Legal Counsel and Head of Government Affairs and Policy for one of the world’s largest biopharmaceutical companies, GlaxoSmithKline, in Australia and New Zealand. As a result, Kelly has a deep understanding of the medical and life sciences industry in Australia and globally, including the impact of government policy on business operations. Kelly was a member of the Medicines Australia taskforce responsible for negotiating and implementing the 2018 Strategic Agreement, and associated legislative amendments and policy reforms, between the innovative medicines industry and the Federal Government.
Kelly advises on a range of issues impacting the healthcare sector, including: Issues impacting the pharmaceutical, vaccines and medical technology industry, including clinical trial governance, regulatory affairs, medical affairs, including the promotion of therapeutic goods, pharmacovigilance, product recalls and class actions, including questions of administrative law and probity, negotiation of special pricing arrangements, vaccine tenders, and deeds of agreement; Legal and policy issues arising from market access for new medical interventions, such as submissions for reimbursement of medical procedures, medicines, vaccines, diagnostics and medical devices, including MSAC and PBAC submissions; Assisting clients engage with the Department of Health in relation to the requirements of the Medicare Benefits Schedule (MBS) and other Government health programs such as the Pharmaceuticals Benefits Scheme (PBS) and incentive payment programs.
Prior to joining Gadens, Kelly served as both Chief Legal Counsel and Head of Government Affairs and Policy for one of the world’s largest biopharmaceutical companies, GlaxoSmithKline, in Australia and New Zealand. As a result, Kelly has a deep understanding of the medical and life sciences industry in Australia and globally, including the impact of government policy on business operations. Kelly was a member of the Medicines Australia taskforce responsible for negotiating and implementing the 2018 Strategic Agreement, and associated legislative amendments and policy reforms, between the innovative medicines industry and the Federal Government.
Kelly advises on a range of issues impacting the healthcare sector, including: Issues impacting the pharmaceutical, vaccines and medical technology industry, including clinical trial governance, regulatory affairs, medical affairs, including the promotion of therapeutic goods, pharmacovigilance, product recalls and class actions, including questions of administrative law and probity, negotiation of special pricing arrangements, vaccine tenders, and deeds of agreement; Legal and policy issues arising from market access for new medical interventions, such as submissions for reimbursement of medical procedures, medicines, vaccines, diagnostics and medical devices, including MSAC and PBAC submissions; Assisting clients engage with the Department of Health in relation to the requirements of the Medicare Benefits Schedule (MBS) and other Government health programs such as the Pharmaceuticals Benefits Scheme (PBS) and incentive payment programs.
Kerry Awerbuch, Partner, Intellectual Property and Technology, Gadens
Kerry is a Partner in the Intellectual Property Team at Gadens with over 15 years' experience. She is an intellectual property lawyer, practising in patent, design, trade mark, copyright and consumer law. As well as having broad litigation and advisory experience.
Kerry has a strong practice in advising clients across the full range of intellectual property and contractual disputes as well as advising clients on strategies for capturing, protecting and driving the value in their intellectual property assets.
Her experience includes advising clients on IP protection, management and ownership strategies, enforcement of IP rights, drafting IP agreements (including patent, design, copyright and trade mark licenses and assignments, collaboration agreements and technology transfer agreements), undertaking IP due diligence, prosecuting trade mark and design applications in Australia and overseas, providing freedom to operate advice, advising on off-patent protection strategies and providing advertising, marketing and product labelling advice.
Kerry has been voted by her peers as a Best Lawyer for Intellectual Property since the 2020 edition of Best Lawyers Australia. She is also currently ranked in Doyle's Guide as a Leading Intellectual Property Lawyer and has also been ranked by WTR1000 since 2020 for Prosecution and Strategy.
Kerry has a strong practice in advising clients across the full range of intellectual property and contractual disputes as well as advising clients on strategies for capturing, protecting and driving the value in their intellectual property assets.
Her experience includes advising clients on IP protection, management and ownership strategies, enforcement of IP rights, drafting IP agreements (including patent, design, copyright and trade mark licenses and assignments, collaboration agreements and technology transfer agreements), undertaking IP due diligence, prosecuting trade mark and design applications in Australia and overseas, providing freedom to operate advice, advising on off-patent protection strategies and providing advertising, marketing and product labelling advice.
Kerry has been voted by her peers as a Best Lawyer for Intellectual Property since the 2020 edition of Best Lawyers Australia. She is also currently ranked in Doyle's Guide as a Leading Intellectual Property Lawyer and has also been ranked by WTR1000 since 2020 for Prosecution and Strategy.
